Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) spanning five years because of the United States' insistence on confidential biological samples.
The decision was revealed following a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government representative later explained that the United States was demanding access to biological samples for scientific study and profit while was unwilling to guarantee the benefits from any future treatments.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more talks to secure a deal agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Context
This rejection follows a comparable case in Kenya, where a court halted a similar deal with the US after concerns were filed about the safety of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and accountability.
According to statements, Sixteen African countries have to date signed these new health pacts, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our country would supply the basic resources for medical research with no certainty that the final treatments would be available to our citizens if a future disease outbreak arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems already established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its information, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We encourage continued dialogue with our US partners on how future co-operation could be structured in a way that respects the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but suggested that negotiations need to persist since much of the country's HIV programmes were funded by international support.
"In cases where technical issues arise, including those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," the group commented.
This impasse underscores the complex debate between receiving vital foreign assistance and protecting a country's data in an increasingly interconnected world.